Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide versus alendronate for new osteoporotic vertebral fractures
jRCTs021250002Suspended
- Sponsor
- Teijin Pharma
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial in osteoporosis comparing Abaloparatide treatment group with Alendronate treatment group (2 arms). Primary endpoint: Change in disease-specific quality of life assessment with the RDQ at 12 weeks. Started Aug 2025; status: suspended.
02
Drugs
abaloparatidealendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCTs021250002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021250002.